Insurance coverage is integral to the accessibility, use, and ultimate impact of digital therapeutics. Inconsistency of decision-making across payors contributes to variable insurance coverage and unequal access to DTx products.
DTA’s Payor Accelerator Board (PAB) is providing critical insight into how payors decide on coverage to develop resources and publications to inform research, evidence generation, and clinical adoption of new technologies. Board members represent key stakeholders, including: